Biofrontera Inc. (BFRI) Aandelenanalyse

Bedrijfsoverzicht

Biofrontera Inc. is a biopharmaceutical entity dedicated to the commercialization of pharmaceutical products designed for the treatment of dermatological conditions within the United States market. The company operates specifically within the Healthcare sector, functioning as a Drug Manufacturer specializing in both specialty and generic pharmaceutical segments. This operational focus allows the firm to target specific therapeutic areas where innovative drug delivery systems and medical devices are required to manage skin health conditions. As of the latest reporting period, the company maintains a market capitalization of $12.00M while generating annual revenue of $41.70M. The organization employs a workforce of 84 individuals to execute its business strategy and manage its product portfolio. These financial figures indicate that Biofrontera is a small-cap enterprise operating with a lean organizational structure, which often correlates with high operational efficiency but limits diversification capabilities compared to larger peers. The relatively modest market capitalization suggests that the market prices the company based on its specific niche potential rather than broad-scale revenue dominance.

Financiële gezondheid

Biofrontera reported a trailing twelve-month revenue of $41.70M, yet the company recorded a net income loss of $10,536,000 and an EBITDA loss of $11,210,000. The significant disparity between the positive revenue figure and the substantial negative net income reveals a cost structure where operating expenses and research costs heavily outweigh gross profits in the current period. The company generated free cash flow of $-2,362,000, which indicates a temporary lack of financial flexibility as the firm consumes cash reserves to fund its ongoing operations and development activities. Despite the cash burn, the company holds $6.40M in cash against $6.16M in debt, resulting in a debt-to-equity ratio of 58.79. This leverage level suggests a balance sheet that is moderately leveraged, relying on shareholder equity rather than excessive debt financing to support its current obligations. The current ratio stands at 1.52, indicating that the company possesses sufficient short-term liquid assets to cover its short-term liabilities without immediate distress. However, the return on equity is reported at -141.3% and the return on assets is -28.0%, which reveals that management has not yet generated positive returns on the capital invested in the business. These negative return metrics reflect the early-stage nature of the company's financial performance and the high investment required to bring pharmaceutical products to market.

Waarderingsbeoordeling

Biofrontera's valuation metrics present a complex picture, with a trailing P/E ratio marked as N/A due to the absence of positive net income over the trailing twelve months. The forward P/E is listed at -4.48, a figure that implies the market expects earnings to remain negative or volatile in the near term, preventing a traditional earnings-based valuation. The price-to-book ratio is 1.14, indicating that the stock trades at a slight premium of 14% above its book value per share. This premium suggests that the market assigns value to the company's intangible assets, such as its intellectual property and patent portfolio, beyond the tangible book value recorded on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.29 and an EV/EBITDA of -1.05, which provide context for investors analyzing the company's revenue efficiency despite current losses. The stock's trading range over the past year spans a high of $1.19 and a low of $0.54. Without a specific current share price provided in the source data to calculate an exact percentage deviation, the valuation context relies on these established 52-week bounds to define the volatility envelope. The beta value is 0.64, which indicates that the stock's price volatility is lower than that of the broader market, moving approximately 36% less than the market index on average.

Growth & Income

The company demonstrated robust revenue growth of 36.2% year-over-year, while earnings growth is listed as N/A due to the company's current unprofitability. The divergence between strong revenue expansion and negative earnings growth implies that the business is scaling its top line faster than it is controlling its operating costs or generating profits from that revenue. Biofrontera does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company does not distribute earnings to shareholders but instead retains all cash flows to reinvest into research, development, and commercialization efforts. The absence of a dividend payout is consistent with the company's life-cycle stage, where capital allocation is directed toward building market share and product pipelines rather than returning capital to investors. The overall growth and income profile is characterized by high revenue momentum supported by a lack of current income generation, requiring investors to evaluate the company based on its potential for future profitability rather than current cash distributions.